Publications

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical pr

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical pr

Magali Rouyer, Stéphane Oudard, Florence Joly, Karim Fizazi, Florence Tubach, Jérémy Jove, Clémentine Lacueille, Stéphanie Lamar

British Journal of Cancer

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, p

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, p

Prof Xavier Pivot, MD, Gilles Romieu, MD, Marc Debled, MD, Prof Jean-Yves Pierga, MD, Prof Pierre Kerbrat, MD, Thomas Bachelot,

Volume 393, ISSUE 10191,